{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T10:09:42Z","timestamp":1788775782621,"version":"build-2803163510"},"reference-count":60,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Immune checkpoint inhibitors have reshaped cancer treatment, but the response patterns they produce\u2014pseudoprogression, dissociated responses, and hyperprogressive disease (HPD)\u2014fit awkwardly into the size-based logic of RECIST 1.1. This narrative review, prepared with reference to the SANRA criteria, follows the evolution of response assessment from RECIST 1.1 through immune-adapted criteria such as iRECIST to functional and molecular imaging and, most recently, artificial intelligence (AI) models trained on longitudinal imaging. One distinction runs through the entire argument: current AI and radiomics models are risk-stratification tools, not diagnostic classifiers of HPD. Because HPD is defined as acceleration of tumor growth relative to a pretreatment trajectory, its diagnosis requires at least three imaging time points (pre-baseline, baseline, and first on-treatment assessment); no single-time-point model, however sophisticated, can reconstruct that trajectory. We appraise Image Biomarker Standardisation Initiative-compliant radiomics, convolutional neural networks, vision transformers, and early longitudinal modeling, and we compare early, joint, and late strategies for fusing imaging with clinical and molecular data. The clinical meaning of reported performance gains is weighed against standard assessment practice. Most evidence remains retrospective, and persistent obstacles include heterogeneous acquisition protocols, small cohorts, missing pre-baseline scans, endpoint misclassification, weak external validation, and limited biological interpretability. Prospective multicenter data collection, transparent model reporting, calibration and domain-shift testing, and biologically anchored validation are prerequisites before imaging-based AI biomarkers can enter routine immuno-oncology care.<\/jats:p>","DOI":"10.3389\/fmed.2026.1954076","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T09:32:31Z","timestamp":1788773551000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Medical imaging in immunotherapy response evaluation: from RECIST to AI-driven longitudinal models, and the distinction between risk prediction and kinetic diagnosis"],"prefix":"10.3389","volume":"13","author":[{"given":"Huzhe","family":"Cui","sequence":"first","affiliation":[{"name":"Department of Radiology, The Affiliated Hospital of Yanbian University (Yanbian Hospital)","place":["Yanji, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengri","family":"Piao","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Affiliated Hospital of Yanbian University (Yanbian Hospital)","place":["Yanji, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songnan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Affiliated Hospital of Yanbian University (Yanbian Hospital)","place":["Yanji, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s00117-025-01552-9","article-title":"iRECIST: assessment of immunotherapy response","volume":"66","author":"Lennartz","year":"2026","journal-title":"Radiologie"},{"key":"B2","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1148\/radiol.2020200443","article-title":"Incidence of pseudoprogression during immune checkpoint inhibitor therapy for solid tumors: a systematic review and meta-analysis","volume":"297","author":"Park","year":"2020","journal-title":"Radiology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1634\/theoncologist.2019-0636","article-title":"Hyperprogression and immune checkpoint inhibitors: hype or progress?","volume":"25","author":"Adashek","year":"2020","journal-title":"Oncologist"},{"key":"B4","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00262-020-02647-z","article-title":"Patterns of progression in patients treated for immuno-oncology antibodies combination","volume":"70","author":"Bernard-Tessier","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40644-019-0281-x","article-title":"iRECIST: how to do it","volume":"20","author":"Persigehl","year":"2020","journal-title":"Cancer Imaging"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e003302","DOI":"10.1136\/jitc-2021-003302","article-title":"Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival","volume":"10","author":"Manitz","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e001343","DOI":"10.1136\/jitc-2020-001343","article-title":"Novel, non-invasive imaging approach to identify patients with advanced non-small cell lung cancer at risk of hyperprogressive disease with immune checkpoint blockade","volume":"8","author":"Vaidya","year":"2020","journal-title":"J Immuno Ther Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s41073-019-0064-8","article-title":"SANRA\u2014a scale for the quality assessment of narrative review articles","volume":"4","author":"Baethge","year":"2019","journal-title":"Res Integr Peer Rev"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e240300","DOI":"10.1148\/ryai.240300","article-title":"Checklist for artificial intelligence in medical imaging (CLAIM): 2024 update","volume":"6","author":"Tejani","year":"2024","journal-title":"Radiol Artif Intell"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e078378","DOI":"10.1136\/bmj-2023-078378","article-title":"TRIPOD\u2009+\u2009AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods","volume":"385","author":"Collins","year":"2024","journal-title":"Br Med J"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e082505","DOI":"10.1136\/bmj-2024-082505","article-title":"PROBAST\u2009+\u2009AI: an updated quality, risk of bias, and applicability assessment tool for prediction models using regression or artificial intelligence methods","volume":"388","author":"Moons","year":"2025","journal-title":"Br Med J"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1007\/s00330-024-11060-4","article-title":"Real-world response assessment of immune checkpoint inhibition: comparing iRECIST and RECIST 1.1 in melanoma and non-small cell lung cancer patients","volume":"35","author":"Nelles","year":"2025","journal-title":"Eur Radiol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1007\/s00330-020-07249-y","article-title":"Comparing RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab in a phase II clinical trial","volume":"31","author":"Ahmed","year":"2021","journal-title":"Eur Radiol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e001499","DOI":"10.1136\/jitc-2020-001499","article-title":"RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in MSI-H\/dMMR mCRC: the GERCOR NIPICOL phase II study","volume":"8","author":"Cohen","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e004849","DOI":"10.1136\/jitc-2022-004849","article-title":"iRECIST and atypical patterns of response to immuno-oncology drugs","volume":"10","author":"Ramon-Patino","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"120","DOI":"10.3390\/cancers13010120","article-title":"Comparison of RECIST 1.1 and iRECIST in patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"13","author":"Park","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"808","DOI":"10.3390\/cancers18050808","article-title":"Artificial intelligence for RECIST-based radiologic treatment response assessment in solid tumors: a systematic review","volume":"18","author":"Leszczy\u0144ska","year":"2026","journal-title":"Cancers (Basel)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"982983","DOI":"10.3389\/fonc.2022.982983","article-title":"Tumor response assessment on imaging following immunotherapy","volume":"12","author":"Berz","year":"2022","journal-title":"Front Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"371","DOI":"10.3390\/cancers12020371","article-title":"Immunotherapy by immune checkpoint inhibitors and nuclear medicine imaging: current and future applications","volume":"12","author":"Decazes","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.clon.2024.06.002","article-title":"Pooled rate of pseudoprogression, patterns of response, and tumor burden analysis in patients undergoing immunotherapy oncologic trials for different malignancies","volume":"36","author":"Morrissey","year":"2024","journal-title":"Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1158\/1078-0432.CCR-16-1741","article-title":"Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1\/PD-L1","volume":"23","author":"Champiat","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1001\/jamaoncol.2018.3676","article-title":"Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1\/PD-L1 inhibitors or with single-agent chemotherapy","volume":"4","author":"Ferrara","year":"2018","journal-title":"JAMA Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1148\/rg.2020200070","article-title":"Assessing immunotherapy with functional and molecular imaging and radiomics","volume":"40","author":"Garc\u00eda-Figueiras","year":"2020","journal-title":"Radiographics"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e202310694","DOI":"10.1002\/anie.202310694","article-title":"Recent advances in the development of non-invasive imaging probes for cancer immunotherapy","volume":"63","author":"Kazim","year":"2024","journal-title":"Angew Chem Int Ed Engl"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e004949","DOI":"10.1136\/jitc-2022-004949","article-title":"Molecular imaging to support cancer immunotherapy","volume":"10","author":"van De Donk","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1038\/s41591-018-0255-8","article-title":"89Zr-atezolizumab Imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer","volume":"24","author":"Bensch","year":"2018","journal-title":"Nat Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"681","DOI":"10.2967\/jnumed.125.271459","article-title":"Feasibility of [89Zr]Zr-atezolizumab immuno-PET for PD-L1 quantification in the clinical work-up of metastatic triple-negative breast cancer","volume":"67","author":"Nijveldt","year":"2026","journal-title":"J Nucl Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"720","DOI":"10.2967\/jnumed.121.262485","article-title":"CD8-targeted PET imaging of tumor-infiltrating T cells in patients with cancer: a phase I first-in-humans study of 89Zr-Df-IAB22M2C","volume":"63","author":"Farwell","year":"2021","journal-title":"J Nucl Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"20027","DOI":"10.1038\/s41598-024-70208-w","article-title":"CT radiomics-based biomarkers can predict response to immunotherapy in hepatocellular carcinoma","volume":"14","author":"Qi","year":"2024","journal-title":"Sci Rep"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e009140","DOI":"10.1136\/jitc-2024-009140","article-title":"Radiomics signature for dynamic monitoring of tumor inflamed microenvironment and immunotherapy response prediction","volume":"13","author":"Bernatowicz","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40364-024-00560-6","article-title":"MRI-derived radiomics assessing tumor-infiltrating macrophages enable prediction of immune-phenotype, immunotherapy response and survival in glioma","volume":"12","author":"Chen","year":"2024","journal-title":"Biomark Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e133","DOI":"10.1016\/S1470-2045(22)00742-2","article-title":"Harnessing imaging tools to guide immunotherapy trials: summary from the NCI cancer imaging steering committee workshop","volume":"24","author":"Shankar","year":"2023","journal-title":"Lancet Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.semcancer.2020.12.005","article-title":"Integrated imaging and molecular analysis to decipher tumor microenvironment in the era of immunotherapy","volume":"84","author":"Wu","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e404","DOI":"10.1016\/S2589-7500(23)00082-1","article-title":"Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study","volume":"5","author":"Saad","year":"2023","journal-title":"Lancet Digit Health"},{"key":"B35","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1148\/radiol.2020191145","article-title":"The image biomarker standardization initiative: standardized quantitative radiomics for high-throughput image-based phenotyping","volume":"295","author":"Zwanenburg","year":"2020","journal-title":"Radiology"},{"key":"B36","doi-asserted-by":"publisher","first-page":"111501","DOI":"10.1016\/j.compbiomed.2026.111501","article-title":"Influence of CT harmonization in longitudinal radiomics for NSCLC immunotherapy response prediction","volume":"203","author":"Farina","year":"2026","journal-title":"Comput Biol Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e012416","DOI":"10.1136\/jitc-2025-012416","article-title":"Clinical-radiomics nomogram integrating lymph node radiomic features to predict immunotherapy response in advanced biliary tract cancers","volume":"13","author":"Li","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"4403","DOI":"10.1007\/s00330-025-11350-5","article-title":"Prediction of immunotherapy response in nasopharyngeal carcinoma: a comparative study using MRI-based radiomics signature and PD-L1 expression score","volume":"35","author":"Mai","year":"2025","journal-title":"Eur Radiol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s40644-024-00779-4","article-title":"Personalized prediction of immunotherapy response in lung cancer patients using advanced radiomics and deep learning","volume":"24","author":"Liao","year":"2024","journal-title":"Cancer Imaging"},{"key":"B40","doi-asserted-by":"publisher","first-page":"785","DOI":"10.21037\/tlcr-24-973","article-title":"Short-term peri- and intra-tumoral CT radiomics to predict immunotherapy response in advanced NSCLC","volume":"14","author":"Wang","year":"2025","journal-title":"Transl Lung Cancer Res"},{"key":"B41","doi-asserted-by":"publisher","first-page":"103000","DOI":"10.1016\/j.media.2023.103000","article-title":"Advances in medical image analysis with vision transformers: a comprehensive review","volume":"91","author":"Azad","year":"2024","journal-title":"Med Image Anal"},{"key":"B42","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/s41746-024-01207-4","article-title":"Harnessing the power of longitudinal medical imaging for eye disease prognosis using transformer-based sequence modeling","volume":"7","author":"Holste","year":"2024","journal-title":"npj Digit Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.21037\/tlcr-24-7","article-title":"Predictive value of delta-radiomic features for prognosis of advanced non-small cell lung cancer patients undergoing immune checkpoint inhibitor therapy","volume":"13","author":"Han","year":"2024","journal-title":"Transl Lung Cancer Res"},{"key":"B44","doi-asserted-by":"publisher","first-page":"104916","DOI":"10.1016\/j.compbiomed.2021.104916","article-title":"Immunotherapy treatment outcome prediction in metastatic melanoma through an automated multi-objective delta-radiomics model","volume":"138","author":"Chen","year":"2021","journal-title":"Comput Biol Med"},{"key":"B45","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.3390\/cancers17223638","article-title":"Integrating multi-omics and medical imaging in AI-based cancer research: an umbrella review of fusion strategies and applications","volume":"17","author":"Marouf","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B46","doi-asserted-by":"publisher","first-page":"81","DOI":"10.21037\/tcr-2025-aw-2287","article-title":"Enhanced CT-based deep learning radiomics and biological correlations for predicting immunotherapy efficacy in advanced non-small cell lung cancer","volume":"15","author":"Zhu","year":"2026","journal-title":"Transl Cancer Res"},{"key":"B47","doi-asserted-by":"publisher","first-page":"103551","DOI":"10.1016\/j.eclinm.2025.103551","article-title":"AI-derived longitudinal and multi-dimensional CT classifier for NSCLC to optimize neoadjuvant chemoimmunotherapy decision: a multicentre retrospective study","volume":"89","author":"Ye","year":"2025","journal-title":"eClinicalMed"},{"key":"B48","doi-asserted-by":"publisher","first-page":"tzad004","DOI":"10.1093\/bjro\/tzad004","article-title":"State of the art: radiomics and radiomics-related artificial intelligence on the road to clinical translation","volume":"6","author":"Majumder","year":"2023","journal-title":"BJR Open"},{"key":"B49","doi-asserted-by":"publisher","first-page":"310","DOI":"10.12688\/openreseurope.21016.1","article-title":"How the first medical imaging cancer atlas EUCAIM was populated: the experience of a reference hospital","volume":"5","author":"Penad\u00e9s Blasco","year":"2025","journal-title":"Open Res Eur"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.3390\/s24051634","article-title":"Building flexible, scalable, and machine learning-ready multimodal oncology datasets","volume":"24","author":"Tripathi","year":"2024","journal-title":"Sensors (Basel)"},{"key":"B51","doi-asserted-by":"publisher","first-page":"102799","DOI":"10.1016\/j.media.2023.102799","article-title":"Imunity: a generalizable VAE-GAN solution for multicenter MR image harmonization","volume":"88","author":"Cackowski","year":"2023","journal-title":"Med Image Anal"},{"key":"B52","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1007\/s00259-024-06708-8","article-title":"Multicenter PET image harmonization using generative adversarial networks","volume":"51","author":"Haberl","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B53","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.3390\/cancers17162679","article-title":"Clinically explainable prediction of immunotherapy response integrating radiomics and clinico-pathological information in non-small cell lung cancer","volume":"17","author":"Mitra","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B54","doi-asserted-by":"publisher","first-page":"32259","DOI":"10.1038\/s41598-025-17718-3","article-title":"Heterogeneity-optimized method for predicting immune checkpoint blockade response","volume":"15","author":"Liang","year":"2025","journal-title":"Sci Rep"},{"key":"B55","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.annonc.2023.10.125","article-title":"Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review","volume":"35","author":"Prelaj","year":"2024","journal-title":"Ann Oncol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.21037\/qims-24-130","article-title":"Integrated radiomics and immune infiltration analysis to decipher immunotherapy efficacy in lung adenocarcinoma","volume":"15","author":"Lei","year":"2025","journal-title":"Quant Imaging Med Surg"},{"key":"B57","doi-asserted-by":"publisher","first-page":"3342","DOI":"10.1097\/JS9.0000000000002322","article-title":"A deep learning-based clinical-radiomics model predicting the treatment response of immune checkpoint inhibitors (ICIs)-based conversion therapy in potentially convertible hepatocelluar carcinoma patients: a tumor marker prognostic study","volume":"111","author":"Lin","year":"2025","journal-title":"Int J Surg"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1038\/s41551-025-01602-6","article-title":"Leveraging multi-modal foundation models for analysing spatial multi-omic and histopathology data","volume":"10","author":"Liu","year":"2026","journal-title":"Nat Biomed Eng"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1225720","DOI":"10.3389\/fonc.2023.1225720","article-title":"Predicting response to immunotherapy in non-small cell lung cancer\u2014from bench to bedside","volume":"13","author":"Montoya","year":"2023","journal-title":"Front Oncol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.diii.2026.02.001","article-title":"Beyond handcrafted radiomics in oncologic imaging: innovations in deep, explainable, multi-site and multi-omics radiomics approaches","volume":"107","author":"Dupont","year":"2026","journal-title":"Diagn Interv Imaging"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1954076\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T09:32:32Z","timestamp":1788773552000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1954076\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":60,"alternative-id":["10.3389\/fmed.2026.1954076"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1954076","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]},"article-number":"1954076"}}